

# Jun Toyohara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9441672/publications.pdf>

Version: 2024-02-01

134  
papers

2,228  
citations

236925

25  
h-index

302126

39  
g-index

137  
all docs

137  
docs citations

137  
times ranked

2528  
citing authors

#	ARTICLE	IF	CITATIONS
1	Testâ€“retest reproducibility of cerebral adenosine A2A receptor quantification using [11C]preladenant. <i>Annals of Nuclear Medicine</i> , 2022, 36, 15-23.	2.2	0
2	Adenosine $A_{2A}$ Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 853-857.	3.9	10
3	Radiosynthesis and <i>in Vivo</i> ; and <i>ex Vivo</i> ; Evaluation of Isomeric [ $^{11}C$ ]methoxy Analogs of Nimesulide as Brain Cyclooxygenase-2-Targeted Imaging Agents. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 94-103.	1.4	4
4	Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [ $^{18}F$ ]FDG and [ $^{11}C$ ]PIB. <i>Medical Physics</i> , 2022, 49, 2995-3005.	3.0	8
5	Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain. <i>Clinical Nuclear Medicine</i> , 2022, 47, e489-e495.	1.3	8
6	Adenosine $A_{2A}$ Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 268-269.	3.9	3
7	Automated production of [18F]MK-6240 on CFN-MPS200. <i>Applied Radiation and Isotopes</i> , 2021, 168, 109468.	1.5	4
8	Preclinical Evaluation of an $^{18}F$ -Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain. <i>ACS Chemical Neuroscience</i> , 2021, 12, 746-755.	3.5	8
9	Interim $^{11}C$ -[methyl- $^{11}C$ ]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [18F]FDG PET. <i>EJNMMI Research</i> , 2021, 11, 13.	2.5	2
10	Effects of 18F-fluorinated neopentyl glycol side-chain on the biological characteristics of stilbene amyloid- $\beta$ PET ligands. <i>Nuclear Medicine and Biology</i> , 2021, 94-95, 38-45.	0.6	6
11	<i>N</i> -Alkyl 3-aminobutanenitrile as a Non-radioactive Side Product in Nucleophilic $^{18}F$ -Fluorination. <i>ChemistrySelect</i> , 2021, 6, 2826-2831.	1.5	5
12	Correlation of $^{11}C$ -[methyl- $^{11}C$ ]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma. <i>EJNMMI Research</i> , 2021, 11, 42.	2.5	1
13	Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4307-4317.	6.4	6
14	Evaluation of P-glycoprotein function at the bloodâ€“brain barrier using [18F]MC225-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4105-4106.	6.4	7
15	Correlation of $^{11}C$ -[methyl- $^{11}C$ ]-thiothymidine PET with Ki-67 immunohistochemistry separately in patients with newly diagnosed and recurrent gliomas. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 1322-1327.	1.1	0
16	First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the bloodâ€“brain barrier. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1240-1252.	2.2	0
17	Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2615-2623.	6.4	2
18	Pharmacokinetic Modeling of ( <i>R</i> )-[ $^{11}C$ ]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates. <i>Molecular Pharmaceutics</i> , 2021, 18, 416-428.	4.6	3

#	ARTICLE	IF	CITATIONS
19	Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astroglialosis in Patients With Neurological Disorders. <i>Clinical Nuclear Medicine</i> , 2021, 46, e31-e33.	1.3	15
20	Radiosynthesis and preliminary evaluation of an <sup>18</sup> F-labeled tubastatin A analog for PET imaging of histone deacetylase 6. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 85-95.	1.0	4
21	Metabolic Network Topology of Alzheimer's Disease and Dementia with Lewy Bodies Generated Using Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 197-207.	2.6	10
22	18F-THK5351 PET Can Identify Astroglialosis in Multiple Sclerosis Plaques. <i>Clinical Nuclear Medicine</i> , 2020, 45, e98-e100.	1.3	19
23	Relationship between the temporal course of astroglialosis and symptom improvement in cerebral infarction: report of a case monitored using 18F-THK5351 positron emission tomography. <i>BMC Medical Imaging</i> , 2020, 20, 81.	2.7	10
24	Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood-Brain Barrier in Non-Human Primates with PET. <i>Molecular Pharmaceutics</i> , 2020, 17, 3477-3486.	4.6	14
25	Mechanical Regulation Underlies Effects of Exercise on Serotonin-Induced Signaling in the Prefrontal Cortex Neurons. <i>IScience</i> , 2020, 23, 100874.	4.1	10
26	Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier. <i>EJNMMI Research</i> , 2020, 10, 84.	2.5	5
27	Synthesis and evaluation of N-isopropyl-p-[11C]methylamphetamine as a novel cerebral blood flow tracer for positron emission tomography. <i>EJNMMI Research</i> , 2020, 10, 115.	2.5	2
28	Texture indices of <sup>4</sup> [methyl-11C]-thiothymidine uptake predict p16 status in patients with newly diagnosed oropharyngeal squamous cell carcinoma: comparison with 18F-FDG uptake. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 20.	1.5	2
29	Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid $\beta$ , an Alzheimer's disease pathology. <i>Aging</i> , 2020, 12, 19701-19710.	3.1	0
30	<sup>4</sup> [methyl-11C]-thiothymidine as a proliferation imaging tracer for detection of colorectal cancer: comparison with 18F-FDG. <i>Annals of Nuclear Medicine</i> , 2019, 33, 822-827.	2.2	6
31	18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study. <i>EJNMMI Research</i> , 2019, 9, 4.	2.5	10
32	Efficacy of <sup>4</sup> [methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study. <i>EJNMMI Research</i> , 2019, 9, 10.	2.5	8
33	A pitfall of white matter reference regions used in [18F] florbetapir PET: a consideration of kinetics. <i>Annals of Nuclear Medicine</i> , 2019, 33, 848-854.	2.2	9
34	Searching for diagnostic properties of novel fluorine-18-labeled d-allose. <i>Annals of Nuclear Medicine</i> , 2019, 33, 855-865.	2.2	4
35	Radiosynthesis of 18F-labeled d-allose. <i>Carbohydrate Research</i> , 2019, 486, 107827.	2.3	1
36	Pre-discard estimation of radioactivated materials in positron emission tomography cyclotron systems and concrete walls of a cyclotron vault. <i>Medical Physics</i> , 2019, 46, 2457-2467.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Unchanged type 1 metabotropic glutamate receptor availability in patients with Alzheimer's disease: A study using <sup>11</sup> C-ITMM positron emission tomography. <i>NeuroImage: Clinical</i> , 2019, 22, 101783.	2.7	12
38	Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. <i>Annals of Nuclear Medicine</i> , 2019, 33, 375-382.	2.2	16
39	Monoamine Oxidase B Binding of <sup>18</sup> F-THK5351 to Visualize Glioblastoma and Associated Gliosis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 507-509.	1.3	15
40	Response of Cerebral Blood Flow and Blood Pressure to Dynamic Exercise: A Study Using PET. <i>International Journal of Sports Medicine</i> , 2018, 39, 181-188.	1.7	9
41	Microglial Activation on <sup>11</sup> C-CB184 PET in a Patient With Cerebellar Ataxia Associated With HIV Infection. <i>Clinical Nuclear Medicine</i> , 2018, 43, e82-e84.	1.3	4
42	Increased Binding Potential of Brain Adenosine A <sub>1</sub> Receptor in Chronic Stages of Patients with Diffuse Axonal Injury Measured with [ <sup>11</sup> C]-8-dicyclopropylmethyl-1-methyl-3-propylxanthine Positron Emission Tomography Imaging. <i>Journal of Neurotrauma</i> , 2018, 35, 25-31.	3.4	9
43	Validation of scatter limitation correction to eliminate scatter correction error in oxygen-15 gas-inhalation positron emission tomography images. <i>Nuclear Medicine Communications</i> , 2018, 39, 936-944.	1.1	0
44	Occupancy of adenosine A <sub>2A</sub> receptors by istradefylline in patients with Parkinson's disease using <sup>11</sup> C-preladenant PET. <i>Neuropharmacology</i> , 2018, 143, 106-112.	4.1	29
45	Dynamic Exercise Elicits Dissociated Changes Between Tissue Oxygenation and Cerebral Blood Flow in the Prefrontal Cortex: A Study Using NIRS and PET. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 269-274.	1.6	7
46	Correlation of <sup>3</sup> H-[methyl- <sup>11</sup> C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas. <i>Annals of Nuclear Medicine</i> , 2018, 32, 634-641.	2.2	2
47	Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases. <i>Molecules</i> , 2018, 23, 300.	3.8	24
48	Usefulness of <sup>11</sup> C-Methionine Positron Emission Tomography for Monitoring of Treatment Response and Recurrence in a Glioblastoma Patient on Bevacizumab Therapy: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 442-449.	0.7	1
49	Reliable radiosynthesis of 4-[ <sup>10</sup> B]borono-2-[ <sup>18</sup> F]fluoro-L-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis. <i>Annals of Nuclear Medicine</i> , 2018, 32, 463-473.	2.2	8
50	Initial Evaluation of an Adenosine A <sub>2A</sub> Receptor Ligand, <sup>11</sup> C-Preladenant, in Healthy Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1464-1470.	5.0	23
51	Age and gender effects of <sup>11</sup> C-ITMM binding to metabotropic glutamate receptor type 1 in healthy human participants. <i>Neurobiology of Aging</i> , 2017, 55, 72-77.	3.1	6
52	Comparison of imaging using <sup>11</sup> C-ITMM and <sup>18</sup> F-FDG for the detection of cerebellar ataxia. <i>Journal of the Neurological Sciences</i> , 2017, 375, 97-102.	0.6	11
53	Determination of radionuclides and radiochemical impurities produced by in-house cyclotron irradiation and subsequent radiosynthesis of PET tracers. <i>Annals of Nuclear Medicine</i> , 2017, 31, 84-92.	2.2	2
54	Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier. <i>Neuropharmacology</i> , 2017, 116, 247-259.	4.1	26

#	ARTICLE	IF	CITATIONS
55	Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction. <i>Clinical Nuclear Medicine</i> , 2017, 42, e523-e524.	1.3	23
56	Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. <i>Physica Medica</i> , 2017, 42, 203-210.	0.7	73
57	Synthesis and basic evaluation of $7\beta$ -(3-[18F]fluoropropyl)-testosterone and $7\alpha$ -(3-[18F]fluoropropyl)-dihydrotestosterone. <i>Annals of Nuclear Medicine</i> , 2017, 31, 53-62.	2.2	1
58	Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [11C]CB184, in healthy human volunteers. <i>EJNMMI Research</i> , 2017, 7, 26.	2.5	6
59	Evaluation of peri-implant bone metabolism under immediate loading using high-resolution Na18F-PET. <i>Clinical Oral Investigations</i> , 2017, 21, 2029-2037.	3.0	7
60	Density of metabotropic glutamate receptors subtype 1 in Parkinson's disease compared to healthy elderly: a ITMM PET study. <i>Journal of the Neurological Sciences</i> , 2017, 381, 806-807.	0.6	1
61	Effects of a novel tungsten-impregnated rubber neck shield on the quality of cerebral images acquired using 15O-labeled gas. <i>Radiological Physics and Technology</i> , 2017, 10, 422-430.	1.9	6
62	PET imaging for altered brain function evoked by exercise: measurements of changes in cerebral blood flow and neurotransmitters. <i>No Junkan Taisha = Cerebral Blood Flow and Metabolism</i> , 2017, 28, 297-302.	0.0	0
63	Age-Related Decrease in Male Extra-Striatal Adenosine A1 Receptors Measured Using 11C-MPDX PET. <i>Frontiers in Pharmacology</i> , 2017, 8, 903.	3.5	9
64	PET Imaging of $^{18}\text{F}$ -FDG, $^{11}\text{C}$ -methionine, $^{11}\text{C}$ -flumazenil, and $^{11}\text{C}$ -4DST in Progressive Multifocal Leukoencephalopathy. <i>Internal Medicine</i> , 2017, 56, 1219-1223.	0.7	9
65	Cerebral Blood Flow during Dynamic Exercise Correlates with Blood Pressure in Autonomic Brain Regions. <i>Medicine and Science in Sports and Exercise</i> , 2017, 49, 824.	0.4	0
66	Preclinical and first-in-man studies of [11C]CB184 for imaging the 18-kDa translocator protein by positron emission tomography. <i>Annals of Nuclear Medicine</i> , 2016, 30, 534-543.	2.2	10
67	Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. <i>Abdominal Radiology</i> , 2016, 41, 521-530.	2.1	12
68	Relationship between type 1 metabotropic glutamate receptors and cerebellar ataxia. <i>Journal of Neurology</i> , 2016, 263, 2179-2187.	3.6	12
69	Optimization of the alkyl side chain length of fluorine-18-labeled $7\beta$ -alkyl-fluoroestradiol. <i>Nuclear Medicine and Biology</i> , 2016, 43, 512-519.	0.6	1
70	Correlation of $^3\text{H}$ -[methyl-11C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with 11C-methionine uptake. <i>Annals of Nuclear Medicine</i> , 2016, 30, 89-96.	2.2	14
71	Comparison of dosimetry between PET/CT and PET alone using 11C-ITMM. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2016, 39, 177-186.	1.3	3
72	(R)-[11C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. <i>Nuclear Medicine and Biology</i> , 2016, 43, 52-62.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Importance of P-gp PET Imaging in Pharmacology. <i>Current Pharmaceutical Design</i> , 2016, 22, 5830-5836.	1.9	7
74	Evaluation of DNA synthesis with carbon-11-labeled 4 $\beta$ -thiothymidine. <i>World Journal of Radiology</i> , 2016, 8, 799.	1.1	5
75	Volumetric comparison of positron emission tomography/computed tomography using 4 $\beta$ -[methyl-11C]-thiothymidine with 2-deoxy-2-18F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma. <i>Nuclear Medicine Communications</i> , 2015, 36, 219-225.	1.1	14
76	Brain histamine H <sub>1</sub> receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 199-206.	2.4	31
77	Comparison of 11C-4 $\beta$ -thiothymidine, 11C-methionine, and 18F-FDG PET/CT for the detection of active lesions of multiple myeloma. <i>Annals of Nuclear Medicine</i> , 2015, 29, 224-232.	2.2	42
78	Synthesis and evaluation of 7 $\beta$ -(3-[18F]fluoropropyl) estradiol. <i>Nuclear Medicine and Biology</i> , 2015, 42, 590-597.	0.6	7
79	In vitro analysis of transport and metabolism of 4 $\beta$ -thiothymidine in human tumor cells. <i>Nuclear Medicine and Biology</i> , 2015, 42, 470-474.	0.6	12
80	Evaluation of [11C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1106-1118.	6.4	14
81	Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [11C]CB184 and [11C]CB190, as a PET tracer for 18kDa translocator protein: direct comparison with [11C](R)-PK11195. <i>Annals of Nuclear Medicine</i> , 2015, 29, 325-335.	2.2	17
82	Comparison of 4 $\beta$ -[methyl-11C]thiothymidine (11C-4DST) and 3 $\beta$ -deoxy-3 $\beta$ -[18F]fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging. <i>EJNMMI Research</i> , 2015, 5, 7.	2.5	16
83	Brain Imaging of Sigma Receptors. , 2014, , 99-112.		0
84	Changes in Cerebral Blood Flow during Steady-State Cycling Exercise: A Study Using Oxygen-15-Labeled Water with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 389-396.	4.3	61
85	Regional Cerebral Glucose Metabolism and Gait Speed in Healthy Community-Dwelling Older Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 1519-1527.	3.6	35
86	A pilot study of 4 $\beta$ -[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer. <i>EJNMMI Research</i> , 2014, 4, 10.	2.5	15
87	Human Brain Imaging of Acetylcholine Receptors. , 2014, , 113-160.		0
88	Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2014, 40, 2701-2706.	2.6	26
89	Basal $\mu$ -opioid receptor availability in the amygdala predicts the inhibition of pain-related brain activity during heterotopic noxious counter-stimulation. <i>Neuroscience Research</i> , 2014, 81-82, 78-84.	1.9	21
90	PET Imaging of Sigma1 Receptors. , 2014, , 741-763.		1

#	ARTICLE	IF	CITATIONS
91	Use of <sup>11</sup> C-4DST-PET for Imaging of Human Brain Tumors. Tumors of the Central Nervous System, 2014, , 41-48.	0.1	2
92	Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Annals of Nuclear Medicine, 2013, 27, 285-296.	2.2	39
93	Preclinical and the first clinical studies on [ <sup>11</sup> C]ITMM for mapping metabotropic glutamate receptor subtype 1 by positron emission tomography. Nuclear Medicine and Biology, 2013, 40, 214-220.	0.6	20
94	Longitudinal observation of [ <sup>11</sup> C]4DST uptake in turpentine-induced inflammatory tissue. Nuclear Medicine and Biology, 2013, 40, 240-244.	0.6	12
95	Initial Human PET Studies of Metabotropic Glutamate Receptor Type 1 Ligand <sup>11</sup> C-ITMM. Journal of Nuclear Medicine, 2013, 54, 1302-1307.	5.0	34
96	Differential human brain activity induced by two perceptually indistinguishable gentle cutaneous stimuli. NeuroReport, 2013, 24, 425-430.	1.2	4
97	<sup>4</sup> â€²-[Methyl- <sup>11</sup> C]-Thiothymidine PET/CT for Proliferation Imaging in Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 199-206.	5.0	43
98	Evaluation of <sup>4</sup> â€²-[Methyl- <sup>11</sup> C]Thiothymidine in a Rodent Tumor and Inflammation Model. Journal of Nuclear Medicine, 2012, 53, 488-494.	5.0	19
99	Roles of Î¶1 receptors in the mechanisms of action of CNS drugs. Translational Neuroscience, 2012, 3, .	1.4	1
100	Re-evaluation of in vivo selectivity of [ <sup>11</sup> C]SA4503 to Î¶1 receptors in the brain: Contributions of emopamil binding protein. Nuclear Medicine and Biology, 2012, 39, 1049-1052.	0.6	12
101	Application of [ <sup>11</sup> C]SA4503 to selection of novel Î¶1 selective agonists. Nuclear Medicine and Biology, 2012, 39, 1117-1121.	0.6	4
102	Differential effects of age on human striatal adenosine A <sub>1</sub> and A <sub>2A</sub> receptors. Synapse, 2012, 66, 832-839.	1.2	18
103	In Vivo Evaluation of <sup>11</sup> C-labeled Three Radioligands for Glycine Transporter 1 in the Mouse Brain. Clinical Psychopharmacology and Neuroscience, 2012, 10, 34-43.	2.0	2
104	Biodistribution and radiation dosimetry of the $\pm$ 7 nicotinic acetylcholine receptor ligand [ <sup>11</sup> C]CHIBA-1001 in humans. Nuclear Medicine and Biology, 2011, 38, 443-448.	0.6	31
105	In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. Nuclear Medicine and Biology, 2011, 38, 517-527.	0.6	12
106	<sup>11</sup> C-Labeled Analogs of Indomethacin Esters and Amides for Brain Cyclooxygenase-2 Imaging: Radiosynthesis, in Vitro Evaluation and in Vivo Characteristics in Mice. Chemical and Pharmaceutical Bulletin, 2011, 59, 938-946.	1.3	13
107	Animal tumor models for PET in drug development. Annals of Nuclear Medicine, 2011, 25, 717-731.	2.2	11
108	Whole-Body Distribution and Brain Tumor Imaging with <sup>11</sup> C-4DST: A Pilot Study. Journal of Nuclear Medicine, 2011, 52, 1322-1328.	5.0	38

#	ARTICLE	IF	CITATIONS
109	Pharmacological Characterization of [3H]CHIBA-3007 Binding to Glycine Transporter 1 in the Rat Brain. PLoS ONE, 2011, 6, e21322.	2.5	9
110	Occupancy of $\alpha 7$ Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [11C]CHIBA-1001 in Healthy Human Subjects. Clinical Psychopharmacology and Neuroscience, 2011, 9, 111-116.	2.0	25
111	In Vivo Evaluation of $\alpha 7$ Nicotinic Acetylcholine Receptor Agonists [11C]A-582941 and [11C]A-844606 in Mice and Conscious Monkeys. PLoS ONE, 2010, 5, e8961.	2.5	31
112	[11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma. Molecular Imaging and Biology, 2010, 12, 181-191.	2.6	54
113	Characterization of [3H]CHIBA-1001 binding to $\alpha 7$ nicotinic acetylcholine receptors in the brain from rat, monkey, and human. Brain Research, 2010, 1348, 200-208.	2.2	27
114	Pharmacological characterization of [125I]CHIBA-1006 binding, a new radioligand for $\alpha 7$ nicotinic acetylcholine receptors, to rat brain membranes. Brain Research, 2010, 1360, 130-137.	2.2	10
115	Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center. Geriatrics and Gerontology International, 2010, 10, S180-96.	1.5	12
116	Recent Development of Radioligands for Imaging $\alpha 7$ Nicotinic Acetylcholine Receptors in the Brain. Current Topics in Medicinal Chemistry, 2010, 10, 1544-1557.	2.1	32
117	$\alpha 7$ Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. Open Medicinal Chemistry Journal, 2010, 4, 37-56.	2.4	56
118	$\alpha 7$ Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease--!2009-10-15--!2009-10-30--!2010-05-27--!. Open Medicinal Chemistry Journal, 2010, 4, 37-56.	2.4	85
119	High occupancy of $\alpha 7$ receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. International Journal of Neuropsychopharmacology, 2009, 12, 1127.	2.1	63
120	Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping $\alpha 7$ nicotinic receptors by positron emission tomography. Annals of Nuclear Medicine, 2009, 23, 301-309.	2.2	75
121	Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nuclear Medicine and Biology, 2009, 36, 379-388.	0.6	21
122	Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 190-196.	1.1	49
123	Feasibility studies of $^{125}I$ -[methyl- $^{11}C$ ]thiothymidine as a tumor proliferation imaging agent in mice. Nuclear Medicine and Biology, 2008, 35, 67-74.	0.6	52
124	Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes. Current Topics in Medicinal Chemistry, 2007, 7, 1790-1799.	2.1	23
125	Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring. Nuclear Medicine and Biology, 2006, 33, 29-35.	0.6	9
126	Alkyl-fluorinated thymidine derivatives for imaging cell proliferation. Nuclear Medicine and Biology, 2006, 33, 765-772.	0.6	20

#	ARTICLE	IF	CITATIONS
127	Alkyl-fluorinated thymidine derivatives for imaging cell proliferation. Nuclear Medicine and Biology, 2006, 33, 751-764.	0.6	14
128	Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. Journal of Nuclear Medicine, 2006, 47, 1717-22.	5.0	33
129	Basic characterization of <sup>64</sup> Cu-ATSM as a radiotherapy agent. Nuclear Medicine and Biology, 2005, 32, 21-28.	0.6	93
130	Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. Nuclear Medicine and Biology, 2003, 30, 687-696.	0.6	22
131	Trends in nucleoside tracers for PET imaging of cell proliferation. Nuclear Medicine and Biology, 2003, 30, 681-685.	0.6	36
132	Pharmacokinetics and metabolism of 5- <sup>125</sup> I-iodo-4'-thio-2'-deoxyuridine in rodents. Journal of Nuclear Medicine, 2003, 44, 1671-6.	5.0	13
133	Basis of FLT as a cell proliferation marker: comparative uptake studies with [ <sup>3</sup> H]thymidine and [ <sup>3</sup> H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nuclear Medicine and Biology, 2002, 29, 281-287.	0.6	100
134	Rationale of 5-( <sup>125</sup> I)-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker. Journal of Nuclear Medicine, 2002, 43, 1218-26.	5.0	24